Department of Gastroenterology, North Zealand University Hospital, Capital Region, Denmark.
Omicron Aps, Department of Statistics, Roskilde, Denmark.
J Crohns Colitis. 2021 Apr 6;15(4):594-602. doi: 10.1093/ecco-jcc/jjaa207.
The disease course of microscopic colitis [MC], encompassing collagenous colitis [CC] and lymphocytic colitis [LC], is not well known. In a Danish nationwide cohort, we evaluated the disease activity patterns as well as the risk of colorectal cancer [CRC] and mortality based on disease severity.
All incident MC patients [n = 14 302] with a recorded diagnosis of CC [n = 8437] or LC [n = 5865] in the Danish Pathology Register, entered between 2001 and 2016, were matched to 10 reference individuals [n = 142 481]. Incident cases of CRC after the index date were captured from the Danish Cancer Registry. Mortality data were ascertained from the Danish Registry of Causes of Death, and information about treatment was obtained from the Danish National Prescription Registry. The risk of CRC and mortality analyses were investigated by Cox regression and Kaplan-Meier estimates.
We identified a self-limiting or transient disease course in 70.6% of LC patients and in 59.9% of CC patients, p <0.001. Less than 5% of MC patients experienced a budesonide-refractory disease course and were treated with immunomodulators or biologic treatment. A total of 2926 [20.5%] MC patients and 24 632 [17.3%] reference individuals died during the study period. MC patients with a severe disease had a relative risk [RR] of mortality of 1.41 (95% confidence interval [CI]: 1.32-1.50) compared with reference individuals. Only 90 MC patients were diagnosed with CRC during follow-up, corresponding to an RR of 0.48 [95% CI: 0.39-0.60].
A majority of MC patients experience an indolent disease course with a lower risk of developing CRC compared with the background population.
显微镜下结肠炎(MC)的病程包括胶原性结肠炎(CC)和淋巴细胞性结肠炎(LC),其疾病活动模式尚不清楚。在丹麦全国范围内的队列研究中,我们根据疾病严重程度评估了疾病的严重程度、结直肠癌(CRC)风险和死亡率。
丹麦病理学登记处记录的 2001 年至 2016 年间所有新确诊的 MC 患者(CC[n=8437]或 LC[n=5865])[n=14302]与 10 个参照个体(n=142481)进行了匹配。在索引日期后从丹麦癌症登记处捕获 CRC 新发病例。从丹麦死因登记处获得死亡率数据,并从丹麦国家处方登记处获得治疗信息。通过 Cox 回归和 Kaplan-Meier 估计来研究 CRC 和死亡率的风险。
我们发现 70.6%的 LC 患者和 59.9%的 CC 患者存在自限性或一过性疾病过程,p<0.001。不到 5%的 MC 患者经历了布地奈德难治性疾病过程,并接受了免疫调节剂或生物治疗。在研究期间,共有 2926 名[20.5%] MC 患者和 24632 名[17.3%]参照个体死亡。患有严重疾病的 MC 患者的死亡率相对风险[RR]为 1.41(95%置信区间[CI]:1.32-1.50),与参照个体相比。在随访期间,仅有 90 名 MC 患者被诊断为 CRC,RR 为 0.48(95%CI:0.39-0.60)。
大多数 MC 患者的疾病呈惰性,与背景人群相比,发生 CRC 的风险较低。